Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose

Merav Mofaz, Matan Yechezkel, Grace Guan, Margaret L. Brandeau, Tal Patalon, Sivan Gazit, Dan Yamin, Erez Shmueli
doi: https://doi.org/10.1101/2021.09.15.21263633
Merav Mofaz
1Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matan Yechezkel
1Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Guan
2Department of Management Science and Engineering, Stanford University, Stanford CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret L. Brandeau
2Department of Management Science and Engineering, Stanford University, Stanford CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tal Patalon
3Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Gazit
3Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Yamin
1Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel
4Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erez Shmueli
1Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel
5MIT Media Lab, Cambridge MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shmueli@tau.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet.

Objective Evaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.

Design A prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination.

Setting An Israel-wide third (booster) vaccination campaign.

Participants A group of 1,609 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of the third vaccine dose.

Measurements Daily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4 smartwatches.

Results The extent of systemic reactions reported following the third (booster) dose administration is similar to that reported following the second dose (p-value=0.305) and considerably greater than that reported following the first dose (p-value<0.001). Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. Focusing on the third dose, reactions were more apparent in younger participants (p-value<0.01), in women (p-value<0.001), and in participants with no underlying medical conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological measures returned to their baseline levels within three days from inoculation with the third dose.

Limitations Participants may not adequately represent the vaccinated population in Israel and elsewhere.

Conclusion Our work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective, particularly in individuals 65+ years of age and those with underlying medical conditions.

Primary funding source European Research Council (ERC) project #949850.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This study is a prospective observational study and does not include any medical intervention.

Funding Statement

This research was supported by the European Research Council (ERC) project #949850 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine Partnership program. MLB and GG received support from the Koret foundation grant for Smart Cities and Digital Living 2030.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Before participating in the study, all subjects were advised, both orally and in writing, as to the nature of the study and gave written informed consent. The study was approved by MHS' Helsinki institutional review board, protocol number 0122-20-MHS.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Larger sample size and additional analyses.

Data Availability

Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the results reported in this paper should contact the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose
Merav Mofaz, Matan Yechezkel, Grace Guan, Margaret L. Brandeau, Tal Patalon, Sivan Gazit, Dan Yamin, Erez Shmueli
medRxiv 2021.09.15.21263633; doi: https://doi.org/10.1101/2021.09.15.21263633
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose
Merav Mofaz, Matan Yechezkel, Grace Guan, Margaret L. Brandeau, Tal Patalon, Sivan Gazit, Dan Yamin, Erez Shmueli
medRxiv 2021.09.15.21263633; doi: https://doi.org/10.1101/2021.09.15.21263633

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)